Conference Call with Indegene Management and Analysts on Q1FY26 Performance and Outlook. Listen to the full earnings transcript.
Healthcare Services company Indegene announced Q1FY26 results Revenue from operations: Rs 7,608 million compared to Rs 6,765 million during Q1FY25. EBITDA: Rs 1,536 million compared to Rs 1,328 million during Q1FY25. EBITDA Margin: 20.2% for Q1FY26. PAT: Rs 1,164 million compared to Rs 877 million during Q1FY25. PAT Margin: 15.3% for Q1FY26. Manish Gupta, Chairman and CEO, Indegene, said: “We continued our growth momentum in Q1FY26, delivering 1.8% growth QoQ in USD. This reflects a strong start to the year and indicates good traction with our clients and from recent deal wins. This was a good quarter for new pipeline growth, and we maintained the momentum on deal wins as well.” “Additionally, we have identified strategic areas of focus for us in FY26 across the organization, spanning various functions. These initiatives will form the bedrock of our medium to long-term growth.” Suhas Prabhu, CFO, Indegene, said: “In Q1FY26, we maintained our trajectory of stable and profitable growth. Both EBITDA margins and PAT margins were on stable lines, even as we continued investing on scaling Tectonic engagements which allow us to move upstream in the marketing value chain; these have now started to generate revenue for us.” “We have a strong cash position and balance sheet and remain focused on M&A; opportunities.” Result PDF